GlassScriptPhysician profile
Shahram Abrishamy
NPI 1649492448
$5,707.34
in general payments reported to CMS, 2019-2025
20 companies · $931 in 2025
The $931 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $211 · 2021: $640 · 2022: $858 · 2023: $1,541 · 2024: $768 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $992.41 | 2019-2024 | Xeomin |
| Amgen INC. | $870.67 | 2023-2025 | Otezla, Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $781.45 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $769.90 | 2019-2025 | Dysport |
| Abbvie INC. | $666.68 | 2019-2025 | Botox |
| Allergan, INC. | $607.50 | 2019-2022 | |
| Genzyme Corporation | $223.38 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $167.73 | 2021-2022 | |
| Janssen Biotech, INC. | $151.06 | 2023-2025 | Carvykti, Rybrevant, Tremfya |
| Gilead Sciences, INC. | $122.09 | 2025 | |
| Revance Therapeutics, INC. | $113.31 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $56.30 | 2019-2022 | |
| Lilly USA, LLC | $34.93 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $34.16 | 2025 | |
| Ucb, INC. | $32.82 | 2025 | Bimzelx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $22.64 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $18.20 | 2021 | |
| Biofrontera INC. | $17.36 | 2025 | |
| Verrica Pharmaceuticals INC. | $15.41 | 2025 | Ycanth |
| Epi Health, LLC | $9.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahram Abrishamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.